Many people evaluate a probiotic based on a single criterion: whether the bacteria can establish long-term colonization in the intestine. There is a common belief that an effective probiotic should permanently inhabit the digestive tract and become part of the body's native microbiota. However, for most probiotic strains, permanent colonization is neither typical nor a prerequisite for clinical effectiveness.
Probiotics are live microorganisms that, when administered in adequate amounts, confer a proven health benefit. Their properties are determined not only by the bacterial species but also by the specific strain, dosage, and conditions of use. Therefore, two products containing similarly named microorganisms may produce different effects. The effectiveness of one strain cannot automatically be attributed to another.
The Microbiota as an Individual Ecosystem
The intestinal microbiota is a complex community of bacteria, fungi, viruses, and other microorganisms. Its composition is shaped by age, diet, previous infections, medication use, lifestyle, environmental factors, and individual physiological characteristics. As a result, every person's microbiota has a unique structure.
A stable microbial community naturally resists colonization by new microorganisms. This phenomenon is known as colonization resistance. While it helps protect against pathogens, it may also prevent long-term establishment of probiotic bacteria.
A study published in Cell demonstrated that individuals responded very differently to the same probiotic formulation. In some participants, the microorganisms were temporarily detected on the intestinal mucosa, whereas in others, the gut ecosystem actively prevented their colonization. The outcome depended on the initial composition of the microbiota and host-specific characteristics.
Therefore, a probiotic that benefits one person may not produce the same results in another. This does not necessarily indicate poor product quality. The reason may be a mismatch between the strain and the clinical objective or individual microbiota resistance.
How a Probiotic Works Even If It Does Not Remain Permanently
Most probiotic microorganisms remain in the digestive tract only temporarily and are gradually eliminated after the course of supplementation ends. Nevertheless, while passing through the intestine, they can interact with the microbial ecosystem, the intestinal mucosa, and local immune mechanisms.
Depending on the specific strain, probiotics may:
- compete with other microorganisms for nutrients and attachment sites;
- produce organic acids, bacteriocins, and other bioactive compounds;
- create conditions that are less favorable for the excessive growth of certain microorganisms;
- influence the barrier function of the intestinal mucosa;
- interact with the local immune system;
- support the metabolic activity of the native microbiota.
These mechanisms are strain-specific and are not shared by all probiotics. Some effects have been well demonstrated in laboratory studies, but separate clinical trials involving humans are required to confirm their clinical relevance. Therefore, antagonistic activity observed under laboratory conditions does not necessarily guarantee therapeutic benefit in an individual patient.
A probiotic can be compared not to a permanent resident but to a temporary regulator of the microbial ecosystem. It does not necessarily remain in the intestine, but if it possesses the appropriate properties, it may influence the conditions in which the native microbiota functions.
Antagonistic Activity Against Opportunistic Microorganisms
One area of personalized microbiome therapy involves the use of strains with potential antagonistic activity against specific microorganisms. These strains may compete for resources, alter environmental acidity, or produce substances that limit the excessive growth of particular bacteria.
The goal of this approach is not the complete elimination of the microbiota but the restoration of ecological balance. Opportunistic microorganisms may be part of a healthy microbiota and require no treatment unless they cause disease. Their presence in laboratory test results alone is not a sufficient reason to prescribe antibiotics, antifungal medications, or probiotics.
In situations where there is no confirmed infection and no indication for targeted antimicrobial therapy, personalized microbiota correction may help avoid unnecessary use of such medications. However, in cases of bacterial or fungal infections requiring etiotropic treatment, probiotics do not replace antibiotics or antifungal drugs.
Why There Is No Universal Probiotic
Probiotic properties are strain-specific. One strain may have strong clinical evidence for preventing antibiotic-associated diarrhea, while another may be studied for certain functional gastrointestinal disorders. Simply increasing the number of bacterial species or colony-forming units in a capsule does not automatically make a probiotic more effective.
The outcome is also influenced by:
- the underlying cause of symptoms;
- the baseline composition of the microbiota;
- diet and dietary fiber intake;
- the condition of the intestinal mucosa;
- the use of antibiotics and other medications;
- age and coexisting medical conditions;
- the dosage, duration of use, and viability of the strain.
For this reason, a probiotic should be selected not based on advertising claims or the number of bacteria listed on the package, but according to the specific clinical objective.
Can a Probiotic Be Chosen Based Only on a Stool Analysis?
No single microbiota test can fully determine which probiotic a patient needs. Stool analysis primarily reflects microorganisms found in the lumen of the large intestine but does not fully characterize the microbial communities associated with the intestinal mucosa, the small intestine, or their functional activity.
Results also depend on the testing method, sample preparation, transportation, and the laboratory's reference database. Therefore, physicians should interpret microbiota analyses together with symptoms, medical history, dietary habits, previous treatments, and other clinical information.
A personalized approach does not mean automatically creating a probiotic based solely on the list of microorganisms identified in a laboratory report. Rather, it is a comprehensive clinical decision that determines whether a probiotic is needed at all, what purpose it should serve, and whether an evidence-based strain exists for that specific indication.
The Gut–Immune–Brain Axis
The microbiota interacts with the nervous and immune systems through microbial metabolites, neural signaling, the intestinal barrier, and inflammatory response mechanisms. This complex network is known as the gut–immune–brain axis.
Disruptions in microbial balance are being investigated in relation to functional gastrointestinal disorders as well as immune, metabolic, and neurological conditions. However, the existence of an association does not prove that alterations in the microbiota are the sole cause of disease or that a probiotic can cure it.
Microbiota modulation in neuroimmunological disorders should be considered part of comprehensive medical care. It does not replace proper diagnosis or standard treatment. Any potential influence on the gut–brain axis depends on the disease, the specific probiotic strain, and individual patient characteristics.
Personalized Microbiome Therapy
The goal of personalized microbiome therapy is not to achieve lifelong colonization by probiotic bacteria but to identify the mechanisms underlying microbial ecosystem disruption and choose an evidence-based strategy for its correction.
A treatment program may include dietary modifications, adequate fiber intake, the use of specific probiotic strains, prebiotics, synbiotics, or other medical interventions. Its content depends on the diagnosis, symptoms, examination results, and treatment tolerability.
Therefore, the absence of long-term colonization does not mean that a probiotic is ineffective. What matters most is whether a particular strain has demonstrated benefits for the specific clinical indication, whether symptoms improve, and whether the treatment is safe. These principles form the foundation of modern personalized microbiome therapy.
References:
1. Zmora N., Zilberman-Schapira G., Suez J. et al. Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features. Cell. 2018;174(6):1388–1405.e21.
https://doi.org/10.1016/j.cell.2018.08.041
2. Sanders M.E., Merenstein D.J., Reid G., Gibson G.R., Rastall R.A. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nature Reviews Gastroenterology & Hepatology. 2019;16:605–616.
https://doi.org/10.1038/s41575-019-0173-3
3. Hill C., Guarner F., Reid G. et al. The ISAPP consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology. 2014;11:506–514.
https://doi.org/10.1038/nrgastro.2014.66
4. Suez J., Zmora N., Segal E., Elinav E. The pros, cons, and many unknowns of probiotics. Nature Medicine. 2019;25:716–729.
https://doi.org/10.1038/s41591-019-0439-x
5. Suez J., Zmora N., Zilberman-Schapira G. et al. Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT. Cell. 2018;174(6):1406–1423.e16.
https://doi.org/10.1016/j.cell.2018.08.047
6. Cryan J.F., O’Riordan K.J., Cowan C.S.M. et al. The Microbiota-Gut-Brain Axis. Physiological Reviews. 2019;99(4):1877–2013.
https://doi.org/10.1152/physrev.00018.2018
7. Belkaid Y., Hand T.W. Role of the Microbiota in Immunity and Inflammation. Cell. 2014;157(1):121–141.
https://doi.org/10.1016/j.cell.2014.03.011
